FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet

Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.